Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Fonar - Where is it going? -- Ignore unavailable to you. Want to Upgrade?

To: valuehunter who wrote (10819)	8/14/1998 12:09:00 PM
From: daveG	Respond to of 19354

.....and page 2 .....with a reminder that this is a very competitive market and fonar is not only one of the smallest players it one of the few pure plays. My take is that the Company is gambling everything on their new products, it is an all or none deal, they know it and the competition knows it. They knew it when Tim formed HMC, Perhaps from past experience with RVDC they knew they may have to fall back on this to save the company....They were just hedging their bets, a smart move if you ask me. They may feel flush with cash but I certainly hope they do not feel they can survive a spending war with any of their competitors...... ********************************************************** With current cancer treatment methods, therapy must always be restricted in the doses that can be applied to the malignant tissue because of the adverse effects on the healthy tissues. The Company expects that once its new OR 360 product is available, treatment agents may be administered directly to the malignant tissue through small catheters or needles. This would allow much larger doses of chemotherapy, x-rays, laser ablation, microwave, or rf to be applied directly and exclusively to the malignant tissue with more effective results. The presence of the MRI image during treatment will help the operator to judge during treatment if the treatment is being effective. The Company's other principal work in progress is a breast MRI scanner. MRI is dramatically superior to the present x-ray technology used in mammograms. MRI takes advantage of the nuclear resonance signal elicited from the body's tissues and the exceptional sensitivity of this signal for detecting disease. Consequently, the MRI image contrasts between healthy and cancerous soft tissue are high. In x-ray mammography, however, the x-ray image contrast between cancerous and healthy tissue is poor, making the detection of breast cancers by the x-ray mammogram less than optimal. An added benefit of MRI mammography relative to x-ray mammography is the elimination of the need for the patient to disrobe and the painful compression of the breast typical of the x-ray mammogram. The patient is scanned in her street clothes in MRI mammography. Moreover MRI mammogram scans the entire chest wall including the axilla for the presence of nodes which the x-ray mammogram cannot reach. A prototype of the Company's breast scanner has been constructed and the breast scanner is awaiting clinical trials. Clinical evaluation is expected to be completed within 16 months, and sales are expected to commence thereafter. *********** But, there IS a business plan.... I agree with everything that Grey Pego said a while back on AOL except for the fact that the or360 does not yet exist